search
Back to results

Use of Technology to Optimize Hypertension Treatment in Elderly People in Primary Care (MINOR)

Primary Purpose

Systemic Arterial Hypertension, Pharmacotherapy, Pharmaceutical Care

Status
Completed
Phase
Not Applicable
Locations
Brazil
Study Type
Interventional
Intervention
MRPA procedure
Pharmaceutical intervention
Sponsored by
Federal University of Bahia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Systemic Arterial Hypertension focused on measuring Systemic Arterial Hypertension;, Technology Applied to Health Care;, Pharmacotherapy;, Pharmaceutical Care.

Eligibility Criteria

60 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Elderly with confirmation of a diagnosis of arterial hypertension (self-report, based on medical report or prescription)
  • Using antihypertensive pharmacotherapy

Exclusion Criteria:

  • Users who, for whatever reason, are unable to perform MRPA.

Sites / Locations

  • Farmácia Escola da UFBA, campus Anísio Teixeira

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Active Comparator

Arm Label

Group control

Intervention group

Arm Description

will be attended by Pharmacists and will have the data collected according to the standard collection instrument, will make MRPA and will receive the report and general guidance on blood pressure control and pharmacotherapy assessment

will be attended by Pharmacists and will have the data collected according to the standard collection instrument, will receive general guidance on blood pressure control and pharmacotherapy assessment, will also do MRPA whose result will guide pharmaceutical suggestions, when necessary, they will also receive a Referral Letter to the Prescriber containing pharmaceutical suggestions for optimization of pharmacotherapy, considering the current clinical protocols.

Outcomes

Primary Outcome Measures

Change in Mean Blood Pressure in MRPA
Change from baseline systolic blood pressure in 45 days

Secondary Outcome Measures

Proportion of patients identified with undertreatment
Patients who had blood pressure above target, needing to add doses or more antihypertensive drugs in pharmacotherapy
Proportion of patients identified with overtreatment
Patients who had blood pressure below the target, needing to prescribe doses or withdraw antihypertensive drugs from pharmacotherapy
Number of drug deprescribing suggestions made
Deprescribing suggestions made by pharmacists based on the average blood pressure value and clinical treatment protocols
Number of pharmacotherapy adequacy suggestions accepted by the prescriber
Number of pharmacotherapy adequacy suggestions accepted by the prescriber

Full Information

First Posted
April 13, 2021
Last Updated
October 3, 2022
Sponsor
Federal University of Bahia
search

1. Study Identification

Unique Protocol Identification Number
NCT04861727
Brief Title
Use of Technology to Optimize Hypertension Treatment in Elderly People in Primary Care
Acronym
MINOR
Official Title
Use of Technology to Optimize Hypertension Treatment in Elderly People in Primary Care
Study Type
Interventional

2. Study Status

Record Verification Date
October 2022
Overall Recruitment Status
Completed
Study Start Date
June 6, 2021 (Actual)
Primary Completion Date
August 30, 2022 (Actual)
Study Completion Date
August 30, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Federal University of Bahia

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The control of blood pressure (BP) in the elderly is influenced by several factors, among them, the measurement methodology. The measurement of BP in the office is prone to failures, so the use of technology associated with blood pressure measurements at home is an alternative to minimize failures and contribute to the optimization of treatment. The objective of this study will be to evaluate the adequacy of the treatment of Systemic Arterial Hypertension (SAH) in primary care using Home Blood Pressure Monitoring (MRPA). Method: Randomized clinical trial with hypertensive patients, aged 60 years or over, attended at the Family Pharmacy service inserted in the primary care of the municipal health network. The subjects who accept to participate in the study will be randomized to the intervention / control groups. submitted to MRPA, will undergo analysis of the pharmacotherapy prescribed for the treatment of SAH, collection of clinical data, which together will support the assessment of the adequacy of the treatment of hypertension. When inadequacies in pharmacotherapy are identified, suggestions for changes will be forwarded to the prescriber / professional or assistant health team, weighted by the pharmacist in agreement with the patient and according to the guidelines of the Brazilian Guideline on Hypertension. The outcomes: changes in treatment and blood pressure control in the intervention and control groups will be evaluated.
Detailed Description
The study will be carried out at a municipal public pharmacy. The subjects will be users of the Family Pharmacy, aged 60 years or over, who seek the service to remove the drugs prescribed for the treatment of Systemic Arterial Hypertension. In order to calculate the sample for this study, the incidence of patients with Hypertension System who need treatment adjustments (under- or over-treatment) will be considered. It is expected that in the intervention group, MRPA indicates that 30% of patients will need to change their pharmacotherapy and, in the control group, using the office measure, 10%. For a two-tailed test with 80% power, 5% sampling error and 95% confidence level, the sample will be 160 users in the intervention group and 160 in the control group. Considering the pandemic of COVID-19 and the risk of infection during care in health services, whether from patients or health professionals from the health care network, the Family Pharmacy already adopts the screening for respiratory symptoms that identify suspected infection by Sars-Cov-2.To minimize the impact of selection and information bias, the following procedure will be used to select individuals: during attendance at the windows, each trained attendant will invite patients with eligibility criteria, when they accept, they will be inserted in the service schedule. The selection for control group and intervention group will take place by drawing from the list of scheduled people, with 3 participants being drawn for the Intervention Group, totaling 160 participants in each group. Data collection will only occur after signing the Informed Consent Form (ICF). The Control Group will be attended by Pharmacists and will have the data collected according to the standard collection instrument, will receive general guidance on blood pressure control and pharmacotherapy assessment. The Intervention Group, in addition to the control group procedures, will also perform the MRPA, the result of which will guide the pharmaceutical suggestions, when necessary, they also received a Letter of Referral to the Prescriber containing pharmaceutical suggestions for optimization of pharmacotherapy, considering the current clinical protocols. In the service, patients and companions will be instructed on preventive measures against Sars-coV-2 infection, in addition to performing hand hygiene with water and liquid soap or 70% alcohol gel. The office will undergo cleaning before and after use, as well as the material, in addition to adopting the time of 15 minutes between appointments, maintaining the ventilation of the room, following all the recommendations of the Ministry of Health. Pharmaceutical evaluation is already a routine of the service. For the purposes of this research, the procedures will be added to standardized instruments and routines to guarantee methodological quality and answer the questions of this research. The Data Collection Form (Appendix I) will be used, which includes the collection of data related to sociodemographic and clinical characteristics. In order to assess adherence, the Portuguese version of the Brief Medication Questionnaire (BMQ) will be used in two stages: during the initial evaluation, when the patient was included in the research and 45 days after the intervention. The pharmaceutical suggestion procedure, for this research, is defined as forwarding a letter of suggestion to the prescriber, previously agreed with the patient, based on clinical evaluation, review of pharmacotherapy, adherence to treatment and result of the MRPA procedure. The definition of the conducts to be adopted will be based on the 8th Brazilian Guideline on Systemic Arterial Hypertension, and in a complementary way - as it is an elderly patient (60 years old or more) - by the Brazilian Consensus on Potential Medicines Inappropriate for the Elderly. The data will be tabulated and analyzed using the SPPS® Statistic 25 software. The Kolmogorov-Sminorv test will be used to assess the data distribution. The paired T test will be used to assess the differences between BP measurements in the office and the MRPA mean. Continuous variables with normal distribution will be presented as means, standard deviations and Odds Ratio. Categorical variables will be presented as a proportion, using the Chi-square test. Values of p <0.05 will be considered significant. To compare the proportion of patients with controlled and uncontrolled blood pressure, before and after application of the intervention, the chi-square test (χ2) will be used. Mean or median values of the MRPA Blood Pressure Mean will also be compared before and after the intervention / description and adherence before and after the MRPA procedure (baseline and at the end of the study) using the paired T test or Wilcoxon.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Systemic Arterial Hypertension, Pharmacotherapy, Pharmaceutical Care
Keywords
Systemic Arterial Hypertension;, Technology Applied to Health Care;, Pharmacotherapy;, Pharmaceutical Care.

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
The Control Group will be attended by Pharmacists and will have the data collected according to the standard collection instrument, will receive general guidance on blood pressure control and pharmacotherapy assessment. The Intervention Group, in addition to the control group procedures, will also perform the MRPA, the result of which will guide the pharmaceutical suggestions, when necessary, they also received a Letter of Referral to the Prescriber containing pharmaceutical suggestions for optimization of pharmacotherapy, considering the current clinical protocols.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
320 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Group control
Arm Type
No Intervention
Arm Description
will be attended by Pharmacists and will have the data collected according to the standard collection instrument, will make MRPA and will receive the report and general guidance on blood pressure control and pharmacotherapy assessment
Arm Title
Intervention group
Arm Type
Active Comparator
Arm Description
will be attended by Pharmacists and will have the data collected according to the standard collection instrument, will receive general guidance on blood pressure control and pharmacotherapy assessment, will also do MRPA whose result will guide pharmaceutical suggestions, when necessary, they will also receive a Referral Letter to the Prescriber containing pharmaceutical suggestions for optimization of pharmacotherapy, considering the current clinical protocols.
Intervention Type
Other
Intervention Name(s)
MRPA procedure
Intervention Description
The patient will receive the device for BP measurement at home for a week and two daily measurements will be taken, one in the morning (between 6 and 10 am) and one in the afternoon / evening (between 6 pm and 10 pm), for seven days. At the end of the procedure, it is expected to record 14 measurements (representing a total of 42 in seven days), but it is considered feasible when at least 10 results are recorded, respecting the number of two measurements per day, in the periods oriented. Participants who do not reach the satisfactory number of measures or do not check between the times mentioned above, will be invited to repeat the procedure
Intervention Type
Other
Intervention Name(s)
Pharmaceutical intervention
Intervention Description
The suggestion procedure, for this research, is defined as the pharmaceutical act of forwarding a letter of suggestion to the prescriber, previously agreed with the patient, based on clinical evaluation, review of pharmacotherapy, adherence to treatment and result of the MRPA procedure.
Primary Outcome Measure Information:
Title
Change in Mean Blood Pressure in MRPA
Description
Change from baseline systolic blood pressure in 45 days
Time Frame
45 days after the intervention
Secondary Outcome Measure Information:
Title
Proportion of patients identified with undertreatment
Description
Patients who had blood pressure above target, needing to add doses or more antihypertensive drugs in pharmacotherapy
Time Frame
Baseline
Title
Proportion of patients identified with overtreatment
Description
Patients who had blood pressure below the target, needing to prescribe doses or withdraw antihypertensive drugs from pharmacotherapy
Time Frame
Baseline
Title
Number of drug deprescribing suggestions made
Description
Deprescribing suggestions made by pharmacists based on the average blood pressure value and clinical treatment protocols
Time Frame
Baseline
Title
Number of pharmacotherapy adequacy suggestions accepted by the prescriber
Description
Number of pharmacotherapy adequacy suggestions accepted by the prescriber
Time Frame
45 days after the intervention

10. Eligibility

Sex
All
Minimum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Elderly with confirmation of a diagnosis of arterial hypertension (self-report, based on medical report or prescription) Using antihypertensive pharmacotherapy Exclusion Criteria: Users who, for whatever reason, are unable to perform MRPA.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marcio GG Oliveira
Organizational Affiliation
Federal University of Bahia
Official's Role
Principal Investigator
Facility Information:
Facility Name
Farmácia Escola da UFBA, campus Anísio Teixeira
City
Vitória Da Conquista
State/Province
Bahia
ZIP/Postal Code
45028440
Country
Brazil

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Use of Technology to Optimize Hypertension Treatment in Elderly People in Primary Care

We'll reach out to this number within 24 hrs